Skip to main content

BA3021-001 A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors.

NCTNCT03504488

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors.

Associated Conditions

Multiple Tumor Types

Principal Investigator

Sponsor

BioAtla LLC